{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:54:20Z","timestamp":1780552460898,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004699","name":"Chung Shan Medical University Hospital","doi-asserted-by":"publisher","award":["CSH-2025-D-005"],"award-info":[{"award-number":["CSH-2025-D-005"]}],"id":[{"id":"10.13039\/501100004699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-03054-5","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:03:42Z","timestamp":1767182622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients"],"prefix":"10.1186","volume":"23","author":[{"given":"Han-Wei","family":"Yeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsien","family":"Chaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Fa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsiang","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Bin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"17","key":"3054_CR1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.2020.19719","volume":"324","author":"C Del Rio","year":"2020","unstructured":"Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324(17):1723\u20134.","journal-title":"JAMA"},{"issue":"1","key":"3054_CR2","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1080\/22221751.2020.1825914","volume":"9","author":"TYM Leung","year":"2020","unstructured":"Leung TYM, et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerging Microbes & Infections. 2020;9(1):2190\u20139.","journal-title":"Emerging Microbes & Infections"},{"key":"3054_CR3","unstructured":"Centers for Disease Control and Prevention. Long COVID basics. February 17, 2025]; Available from: https:\/\/www.cdc.gov\/covid\/long-term-effects\/index.html"},{"key":"3054_CR4","unstructured":"Organisation for Economic Co-operation and Development. The impacts of long COVID across OECD countries. 2024 February 17, 2025]; Available from: https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2024\/06\/the-impacts-of-long-covid-across-oecd-countries_f662b21c\/8bd08383-en.pdf"},{"issue":"3","key":"3054_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133\u201346.","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"3054_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/cid\/ciac961","volume":"76","author":"MM Robertson","year":"2023","unstructured":"Robertson MM, et al. The epidemiology of long coronavirus disease in US adults. Clin Infect Dis. 2023;76(9):1636\u201345.","journal-title":"Clin Infect Dis"},{"key":"3054_CR7","doi-asserted-by":"publisher","DOI":"10.2196\/42315","volume":"9","author":"MC Wong","year":"2023","unstructured":"Wong MC, et al. Epidemiology, symptomatology, and risk factors for long COVID symptoms: population-based, multicenter study. JMIR Public Health Surveill. 2023;9:e42315.","journal-title":"JMIR Public Health Surveill"},{"key":"3054_CR8","doi-asserted-by":"publisher","first-page":"102607","DOI":"10.1016\/j.eclinm.2024.102607","volume":"71","author":"AH Heald","year":"2024","unstructured":"Heald AH, et al. The prevalence of long COVID in people with diabetes mellitus-evidence from a UK cohort. EClinicalMedicine. 2024;71:102607.","journal-title":"EClinicalMedicine"},{"key":"3054_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9061211","author":"M Norouzi","year":"2021","unstructured":"Norouzi M, et al. Type-2 diabetes as a risk factor for severe COVID-19 infection. Microorganisms. 2021. https:\/\/doi.org\/10.3390\/microorganisms9061211.","journal-title":"Microorganisms"},{"key":"3054_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.780663","volume":"13","author":"P Kazakou","year":"2022","unstructured":"Kazakou P, et al. Diabetes and COVID-19; a bidirectional interplay. Front Endocrinol (Lausanne). 2022;13:780663.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3054_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14090911","author":"DE Man","year":"2024","unstructured":"Man DE, et al. Insulin resistance in long COVID-19 syndrome. J Pers Med. 2024. https:\/\/doi.org\/10.3390\/jpm14090911.","journal-title":"J Pers Med"},{"issue":"3","key":"3054_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.5530\/jyp.2024.16.59","volume":"16","author":"NE Varghese","year":"2024","unstructured":"Varghese NE, et al. Unraveling the nexus: Post-COVID hyperglycaemia and diabetes-a comprehensive review of the intricate interplay and implications for glycemic control. J Young Pharm. 2024;16(3):456\u201360.","journal-title":"J Young Pharm"},{"issue":"8","key":"3054_CR13","volume":"3","author":"M Aljadah","year":"2024","unstructured":"Aljadah M, et al. Clinical implications of COVID-19-related endothelial dysfunction. JACC: Advances. 2024;3(8):101070.","journal-title":"JACC: Advances"},{"issue":"1","key":"3054_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10456-023-09878-5","volume":"27","author":"X Wu","year":"2024","unstructured":"Wu X, et al. Damage to endothelial barriers and its contribution to long COVID. Angiogenesis. 2024;27(1):5\u201322.","journal-title":"Angiogenesis"},{"key":"3054_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biom14080965","author":"H Yanai","year":"2024","unstructured":"Yanai H, et al. The significance of endothelial dysfunction in long COVID-19 for the possible future pandemic of chronic kidney disease and cardiovascular disease. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14080965.","journal-title":"Biomolecules"},{"key":"3054_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1011936","volume":"10","author":"RN Low","year":"2023","unstructured":"Low RN, Low RJ, Akrami A. A review of cytokine-based pathophysiology of long COVID symptoms. Front Med (Lausanne). 2023;10:1011936.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3054_CR17","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.","journal-title":"Nat Commun"},{"key":"3054_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107055","volume":"200","author":"P Mone","year":"2024","unstructured":"Mone P, et al. Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease. Pharmacol Res. 2024;200:107055.","journal-title":"Pharmacol Res"},{"issue":"7","key":"3054_CR19","first-page":"1","volume":"9","author":"R Deol","year":"2024","unstructured":"Deol R, Bashir DS. Exploring the complications of TYPE 2 DIABETES MELLITUS: pathophysiology and management strategies. EPRA Int J Res Dev (IJRD). 2024;9(7):1\u201310.","journal-title":"EPRA Int J Res Dev (IJRD)"},{"issue":"6","key":"3054_CR20","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s13300-019-00700-4","volume":"10","author":"S Kalra","year":"2019","unstructured":"Kalra S, Aggarwal S, Khandelwal D. Thyroid dysfunction and type 2 diabetes mellitus: screening strategies and implications for management. Diabetes Ther. 2019;10(6):2035\u201344.","journal-title":"Diabetes Ther"},{"issue":"5","key":"3054_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.4239\/wjd.v15.i5.1001","volume":"15","author":"D Nitzke","year":"2024","unstructured":"Nitzke D, et al. Increasing dietary fiber intake for type 2 diabetes mellitus management: a systematic review. World J Diabetes. 2024;15(5):1001\u201310.","journal-title":"World J Diabetes"},{"key":"3054_CR22","doi-asserted-by":"publisher","first-page":"1349069","DOI":"10.3389\/fphar.2024.1349069","volume":"15","author":"WJ Fu","year":"2024","unstructured":"Fu WJ, et al. Emerging role of antidiabetic drugs in cardiorenal protection. Front Pharmacol. 2024;15:1349069.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3054_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2017","unstructured":"Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"12","key":"3054_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70088","volume":"17","author":"Y Takahashi","year":"2024","unstructured":"Takahashi Y, et al. Long-term benefit of SGLT2 inhibitors to prevent heart failure hospitalization in patients with diabetes, with potential time-varying benefit. Clin Transl Sci. 2024;17(12):e70088.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"3054_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12916-023-02737-6","volume":"21","author":"ER Pfaff","year":"2023","unstructured":"Pfaff ER, et al. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21(1):58.","journal-title":"BMC Med"},{"issue":"9","key":"3054_CR26","doi-asserted-by":"publisher","first-page":"e1003773","DOI":"10.1371\/journal.pmed.1003773","volume":"18","author":"M Taquet","year":"2021","unstructured":"Taquet M, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773.","journal-title":"PLoS Med"},{"issue":"1","key":"3054_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12939-023-02072-5","volume":"22","author":"J Cohen","year":"2023","unstructured":"Cohen J, van der Meulen Y, Rodgers. An intersectional analysis of long COVID prevalence. Int J Equity Health. 2023;22(1):261.","journal-title":"Int J Equity Health"},{"issue":"Suppl 3","key":"3054_CR28","doi-asserted-by":"publisher","first-page":"ckae144811","DOI":"10.1093\/eurpub\/ckae144.811","volume":"34","author":"J Coste","year":"2024","unstructured":"Coste J, et al. Difference in long COVID prevalence due to different definitions and long COVID related risk factors. Eur J Public Health. 2024;34(Suppl 3):ckae144811.","journal-title":"Eur J Public Health"},{"issue":"3","key":"3054_CR29","first-page":"e36325","volume":"15","author":"SK Mudgal","year":"2023","unstructured":"Mudgal SK, et al. Pooled prevalence of long COVID-19 symptoms at 12 months and above follow-up period: a systematic review and meta-analysis. Cureus. 2023;15(3):e36325.","journal-title":"Cureus"},{"issue":"7","key":"3054_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","volume":"44","author":"L Lipscombe","year":"2020","unstructured":"Lipscombe L, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes. 2020;44(7):575\u201391.","journal-title":"Can J Diabetes"},{"key":"3054_CR31","doi-asserted-by":"crossref","unstructured":"Farazul H, et al. Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns. Exploration of Medicine; 2024.","DOI":"10.37349\/emed.2024.00255"},{"issue":"9","key":"3054_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","volume":"11","author":"R Adhikari","year":"2022","unstructured":"Adhikari R, et al. National trends in use of Sodium-Glucose Cotransporter-2 inhibitors and Glucagon-like Peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. 2022;11(9):e023811.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"3054_CR33","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","volume":"15","author":"S Seidu","year":"2024","unstructured":"Seidu S, et al. SGLT2 inhibitors - the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. Diabetes Ther. 2024;15(5):1099\u2013124.","journal-title":"Diabetes Ther"},{"issue":"8","key":"3054_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032397","volume":"13","author":"HC Chang","year":"2024","unstructured":"Chang HC, et al. Sodium glucose transporter 2 inhibitors versus Metformin on cardiovascular and renal outcomes in patients with diabetes with low cardiovascular risk: a nationwide cohort study. J Am Heart Assoc. 2024;13(8):e032397.","journal-title":"J Am Heart Assoc"},{"key":"3054_CR35","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365.","journal-title":"BMJ"},{"key":"3054_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.047965","author":"CV Dave","year":"2021","unstructured":"Dave CV, et al. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation. 2021. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047965.","journal-title":"Circulation"},{"issue":"9","key":"3054_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(9):1117\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"3054_CR38","doi-asserted-by":"publisher","first-page":"1045235","DOI":"10.3389\/fphar.2022.1045235","volume":"13","author":"D Wang","year":"2022","unstructured":"Wang D, et al. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:1045235.","journal-title":"Front Pharmacol"},{"key":"3054_CR39","doi-asserted-by":"publisher","first-page":"1008922","DOI":"10.3389\/fcvm.2022.1008922","volume":"9","author":"L Scisciola","year":"2022","unstructured":"Scisciola L, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: data from basic science and clinical trials. Front Cardiovasc Med. 2022;9:1008922.","journal-title":"Front Cardiovasc Med"},{"key":"3054_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10110465","author":"M Koutentakis","year":"2023","unstructured":"Koutentakis M. The ketogenic effect of SGLT-2 inhibitors\u2014beneficial or harmful? J Cardiovasc Dev Dis. 2023. https:\/\/doi.org\/10.3390\/jcdd10110465.","journal-title":"J Cardiovasc Dev Dis"},{"key":"3054_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213","author":"A Pawlos","year":"2021","unstructured":"Pawlos A, et al. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26237213.","journal-title":"Molecules"},{"issue":"1","key":"3054_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/0127724328281178240225082456","volume":"20","author":"M Sotoudeheian","year":"2025","unstructured":"Sotoudeheian M. Targeting SIRT1 by scopoletin to inhibit XBB.1.5 COVID-19 lifecycle. Current Reviews in Clinical and Experimental Pharmacology. 2025;20(1):4\u201313.","journal-title":"Current Reviews in Clinical and Experimental Pharmacology"},{"issue":"5","key":"3054_CR43","first-page":"686","volume":"51","author":"P Zhang","year":"2021","unstructured":"Zhang P, Zhao T, Zhou W. The clinical significance of SIRT3 in COVID-19 patients: a single center retrospective analysis. Ann Clin Lab Sci. 2021;51(5):686\u201393.","journal-title":"Ann Clin Lab Sci"},{"key":"3054_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae257","author":"A Mroueh","year":"2024","unstructured":"Mroueh A, et al. SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance. Cardiovasc Res. 2024. https:\/\/doi.org\/10.1093\/cvr\/cvae257.","journal-title":"Cardiovasc Res"},{"issue":"Supplement 1","key":"3054_CR45","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1182\/blood-2024-202339","volume":"144","author":"L Stanger","year":"2024","unstructured":"Stanger L, et al. Comparison of the anti-platelet and anti-thrombotic effects of the dual SGLT1\/2 inhibitor Sotagliflozin to the relatively selective SGLT2 inhibitor empagliflozin. Blood. 2024;144(Supplement 1):3933\u20133933.","journal-title":"Blood"},{"issue":"4","key":"3054_CR46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41401-022-00998-0","volume":"44","author":"SW Xu","year":"2023","unstructured":"Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2023;44(4):695\u2013709.","journal-title":"Acta Pharmacol Sin"},{"key":"3054_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176708","author":"L Goedeke","year":"2024","unstructured":"Goedeke L, et al. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI176708.","journal-title":"J Clin Invest"},{"key":"3054_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168676","author":"D Troise","year":"2024","unstructured":"Troise D, et al. mTOR and SGLT-2 inhibitors: their synergistic effect on age-related processes. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25168676.","journal-title":"Int J Mol Sci"},{"key":"3054_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajmo.2023.100033","volume":"9","author":"K Huerne","year":"2023","unstructured":"Huerne K, et al. Epidemiological and clinical perspectives of long COVID syndrome. American Journal of Medicine Open. 2023;9:100033.","journal-title":"American Journal of Medicine Open"},{"key":"3054_CR50","doi-asserted-by":"publisher","first-page":"1085020","DOI":"10.3389\/fpubh.2023.1085020","volume":"11","author":"RYK Chu","year":"2023","unstructured":"Chu RYK, et al. A global scale COVID-19 variants time-series analysis across 48 countries. Front Public Health. 2023;11:1085020.","journal-title":"Front Public Health"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-03054-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03054-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-03054-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:46:27Z","timestamp":1770036387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-025-03054-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3054"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-03054-5","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Institutional Review Board of Chung Shan Medical University Hospital (IRB number: CS2-23180). Consent to participate was waived, as TriNetX had obtained a waiver of informed consent from the Western Institutional Review Board. All data and statistical summaries were presented in aggregated form, and no identifiable personal information was accessible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data were anonymized, and no personally identifiable information was accessible or shared. Only aggregated results were reported; therefore, informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}